West Pharmaceutical (NYSE: WST) exec sells 2,817 shares after option exercise

Rhea-AI Filing Summary

West Pharmaceutical Services senior vice president and chief HR officer Annette F. Favorite exercised stock options and sold shares of common stock. On April 27, she exercised options to acquire 2,817 shares at $83.47 per share and then sold 2,817 shares in an open-market transaction at a weighted average price of $305.2018 per share.

After these transactions, she directly holds 16,828.4906 shares of common stock and indirectly holds 4,966.6170 shares through a Non-Qualified Deferred Compensation Plan, showing she retains a meaningful equity stake in the company despite the net sale.

Insider Trade Summary

Net Seller: 2,817 shares ($859,753)

Net Sell 4 txns

Insider Favorite Annette F

Role Sr. VP & Chief HR Officer

Sold 2,817 shs ($860K)

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	2,817	$0.00	--
Exercise	Common Stock	2,817	$83.47	$235K
Sale	Common Stock	2,817	$305.2018	$860K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Options (Right to Buy) — 5,635 shares (Direct, null); Common Stock — 19,645.491 shares (Direct, null); Common Stock — 4,966.617 shares (Indirect, Non-Qualified Deferred Compensation Plan)

Footnotes (1)

1. The price reported in Column 4 is a weighted average price. This award granted on February 21, 2017 vested in four equal annual installments beginning on February 21, 2018.

Key Figures

Shares sold: 2,817 shares Sale price (weighted average): $305.2018 per share Options exercised: 2,817 shares +5 more

8 metrics

Shares sold 2,817 shares Open-market sale of common stock on April 27

Sale price (weighted average) $305.2018 per share Price for 2,817 common shares sold

Options exercised 2,817 shares Common stock acquired via option exercise

Option exercise price $83.47 per share Strike price for exercised stock options

Direct holdings after transactions 16,828.4906 shares Common stock directly held post-transaction

Indirect holdings after transactions 4,966.6170 shares Common stock held via Non-Qualified Deferred Compensation Plan

Remaining options 5,635.0000 options Stock Options (Right to Buy) position after exercise

Option expiration date February 21, 2027 Expiration of exercised option grant originally dated 2017-02-21

Key Terms

Non-Qualified Deferred Compensation Plan, Stock Options (Right to Buy), weighted average price, Exercise or conversion of derivative security

4 terms

Non-Qualified Deferred Compensation Plan financial

"nature_of_ownership: "Non-Qualified Deferred Compensation Plan""

An arrangement where an employer agrees to pay part of an employee’s salary or bonus at a later date, often to attract or keep key staff. Think of it as a company IOU or a delayed paycheck held on the company’s books rather than in a protected retirement account; investors care because these promises create future cash obligations that are typically unsecured and depend on the company’s financial health, affecting risk, liabilities, and cash-flow planning.

Stock Options (Right to Buy) financial

"security_title: "Stock Options (Right to Buy)""

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Favorite Annette F

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PENNSYLVANIA 19341

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP & Chief HR Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/27/2026		M		2,817	A	$83.47	19,645.4906	D
Common Stock	04/27/2026		S		2,817	D	$305.2018(1)	16,828.4906	D
Common Stock								4,966.617	I	Non-Qualified Deferred Compensation Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$83.47	04/27/2026		M			2,817	02/21/2018(2)	02/21/2027	Common Stock	2,817	$0	5,635	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price.

2. This award granted on February 21, 2017 vested in four equal annual installments beginning on February 21, 2018.

	/s/ Louis Lalli, as an agent for Annette Favorite	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did West Pharmaceutical (WST) report for Annette F. Favorite?

Annette F. Favorite exercised options for 2,817 West Pharmaceutical common shares at $83.47 and sold 2,817 shares at a weighted average price of $305.2018. These transactions occurred on April 27 and were reported on a Form 4 insider filing.

How many West Pharmaceutical (WST) shares did the executive sell and at what price?

Annette F. Favorite sold 2,817 shares of West Pharmaceutical common stock in an open-market transaction at a weighted average price of $305.2018 per share. The sale was reported with transaction code S, indicating an open-market or private transaction.

What stock options did the West Pharmaceutical (WST) executive exercise?

She exercised stock options covering 2,817 shares of West Pharmaceutical common stock at an exercise price of $83.47 per share. The options were originally granted on February 21, 2017 and vested in four equal annual installments beginning February 21, 2018.

How many West Pharmaceutical (WST) shares does Annette F. Favorite hold after the transactions?

Following the reported transactions, she directly holds 16,828.4906 West Pharmaceutical common shares. In addition, she indirectly holds 4,966.6170 shares through a Non-Qualified Deferred Compensation Plan, providing combined direct and indirect exposure to the company’s equity.

What does the Non-Qualified Deferred Compensation Plan mean for West Pharmaceutical (WST) share ownership?

The Non-Qualified Deferred Compensation Plan holds 4,966.6170 West Pharmaceutical common shares for Annette F. Favorite as an indirect ownership position. This structure reflects compensation deferred into company stock rather than cash, aligning a portion of her compensation with West’s share performance.

Was the reported West Pharmaceutical (WST) sale a routine open-market transaction?

The Form 4 identifies the 2,817-share disposition with transaction code S, described as a sale in the open market or private transaction. Footnotes state the reported price is a weighted average, indicating execution across multiple trades aggregated at a single average price.